Parkinson's disease (PD) spreads inside the brain via the release of an abnormal form of the protein alpha-synuclein from diseased neurons. When healthy brain cells take it up, this triggers misfolding and aggregation of the normal alpha-synuclein inside those cells. Thus, causing the spread of abnormal alpha-synuclein within the brain, leading to the symptoms of PD. This project aims to bioengineer protein nanocages to selectively capture abnormal alpha-synuclein stopping its transmission and progression. This work is the focus of MQ's SPARK team. SPARK is a 2-year program that will help drive the clinical translation and commercialisation of this research.
|Effective start/end date||12/10/19 → 11/10/20|